Sierra Announces Promising Preliminary Efficacy in SRA737 Clinical Program & Outlines Potential Path to Registration
(WorldNews Canada)

Sierra Announces Promising Preliminary Efficacy in SRA737 Clinical Program & Outlines Potential Path to Registration - Sierra reports 30% response rate for SRA737+LDG in anogenital cancer - - Anti-cancer activity demonstrated across multiple indications and genetic contexts in preliminary Phase 1/2 data presentations at ASCO - - Sierra to discuss clinical findings and possible next steps for SRA737 at Analyst & Investor Event at 6:00 am CTon June 3, 2019featuring distinguished oncologists Professor Johann de Bonoand Dr. Rebecca Kristeleit - VANCOUVER, June 1, 2019/CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the...